#### Association of FADS2 rs174575 gene polymorphism and insulin resistance in type 2 diabetes mellitus

Shilpa S Shetty<sup>1</sup>, Suchetha Kumari N<sup>2</sup>, Harshini Devi<sup>1</sup>, Sharmila KP<sup>1</sup>, Srinidhi Rai<sup>2</sup>

1. Central Research Laboratory, K.S. Hegde Medical Academy, Nitte (Deemed to be University).

2. Department of Biochemistry, K.S. Hegde Medical Academy, Nitte (Deemed to be University).

#### Abstract

**Background:** Many risk factors contribute to the pathogenesis of diabetes. Gene and lifestyle factors are considered to be the major contributors. A dietary pattern is attributed to be one of the lifestyle risk factors favoring diabetes. The present study aims to find an association between fatty acid desaturase (FADS) gene polymorphism and glycemic profile in type 2 diabetes mellitus (T2DM).

**Methodology:** A total of 429 subjects were included in the study on the basis of inclusion and exclusion criteria, of which 213 and 216 subjects were diabetic and control, respectively. Body mass index was calculated. Fasting plasma glucose, gly-cated hemoglobin (HbA1c) and insulin were measured using commercially available kits. rs174575 of FADS2 was selected based on previous publications and identified using the dbSNP database. To compare the biochemical parameters with the genotype, the following three models were used: additive model (CC vs CG vs GG), dominant model (CC + CG vs GG), and recessive model (CC vs CG + GG).

**Results and Discussion:** FBS, HbA1c, insulin, HOMA-IR, and HOMA-B exhibited a high and statistically significant difference between subjects and controls. The three models exhibited a statistically significant difference between FBS, HO-MA-IR, and HOMA- B (p<0.05).

**Conclusion:** The distribution of rs174575 genotype differed significantly between the subjects and controls in the present study. The study revealed that genetic variation in FADS2 is an additional facet to consider while studying the risk factors of T2DM.

Keywords: Fatty acid desaturase; gene polymorphism; type 2 diabetes mellitus.

DOI: https://dx.doi.org/10.4314/ahs.v20i4.30

**Cite as:** Shetty SS, Suchetha KN, Devi H, Sharmila KP, Rai S. Association of EADS2 rs174575 gene polymorphism and insulin resistance in type 2 diabetes mellitus. Afri Health Sci. 2020;20(4):1770-6. https://dx.doi.org/10.4314/ahs.v20i4.30

#### Introduction

Insulin resistance (IR) is a precursor of type 2 diabetes mellitus (T2DM). Insulin resistance is multifaceted, and the etiology of insulin resistance is complicated with implications from several factors; thus, deciphering T2DM remains challenging. Improved understanding and the risk prediction of the pathogenesis of insulin resistance is crucial<sup>1</sup>. Evidence suggests that oxidative stress; inflammation; and genetic, habitual, environmental, and epigenetic factors are involved<sup>2</sup>. The epidemiological profile of T2DM in India greatly differs from that in the west. Despite low body mass index (BMI), Asian–Indians have a group of clinical and biochemical traits, which is referred to as the "Asian–Indian phenotype," making them more susceptible to the

**Corresponding author:** Shilpa S Shetty, Central Research Laboratory, K.S. Hegde Medical Academy, Nitte (Deemed to be University) Email: shilpajshetty@nitte.edu.in

development of T2DM<sup>3</sup>; 80% of patients with T2DM in India are non-obese, and 1/4th of T2DM in India are of BMI < 19 kg/m<sup>2</sup>. The dietary patterns of Indians are vastly different from a typical "western" diet, with relatively high carbohydrate intake and low fat intake. The main sources of fat are of plant origin rather than animal origin because the majority of population is vegetarian, resulting in a diet that is relatively low in saturated fatty acids (SFAs), high in n-6 polyunsaturated fatty acids (PUFAs), and very low in n-3 PUFAs. Though this appears as a good dietary composition as per global standards, the undeniable increase in the incidence of obesity, diabetes, and cardiovascular diseases in India requires immediate attention. Fats are the main sources of energy for the body, but the type and total amount of fat consumed daily play an important role in maintaining the state of health. The dietary fatty acids in the body undergo a series of enzyme catalyzed reaction to produce bioactive molecules. FADS is one of the major genes associated with the desaturation of FAs. D6D and D5D are encoded by FADS2 and FADS1, respectively, located on chromosome 11<sup>4</sup>. Polymorphism in

African Health Sciences

<sup>© 2020</sup> Shetty SS et al. Licensee African Health Sciences. This is an Open Access article distributed under the terms of the Creative commons Attribution License (https://creativecommons.org/licenses/BY/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

FADS has an especially strong association with the high plasma proportion of arachidonic acid that is known to be a precursor for bodily inflammation <sup>5,6</sup>. The alteration in FA composition results in altered metabolic function, thereby increasing or decreasing the risk of disease because PUFA also acts as biological ligands to functional pathways. Several studies have reported that the desaturation pathway is highly important for glucose homeostasis in the human body. Our current knowledge of the impact of genetic polymorphisms and their potential role in the development of diseases is limited. Therefore, SNPs in FADS cluster should be identified and characterized, thereby providing a new sight to the role of fatty acid gene polymorphism in insulin resistance and T2DM and enabling the development new treatment regimens for the prevention and management of T2DM.

# Materials and Method Study Design and Population

This study was reviewed and approved for human subjects by the Central Ethics Committee of Nitte (Deemed to be University); Ref NU/CEC/PhD-16/2014 dated 9-10-2014. A total of 429 subjects were included in the study on the basis of inclusion and exclusion criteria; there were 213 (49.70%) subjects with T2DM (diabetic group) and 216 (50.30%) were controls (control group). The control group included 105 (48.60%) males and 111 (51.40%) females, whereas the diabetic group included 136 (63.80%) males and 77 (36.20%) females. Informed consent was duly signed by each subject.

#### Inclusion and Exclusion Criteria Diabetic Group Inclusion Criteria

• Subjects with T2DM according to ADA criteria 6 diagnosed for at least 3 months prior to screening.

• Subjects in the age group of 30–60 years from both the sexes.

# Exclusion /Criteria

• Pregnant women.

#### Control Group Inclusion Criteria

• Subjects in the age group of 30–60 years of both sexes visiting for regular health check-ups.

# **Exclusion Criteria**

• Pregnant women.

Anthropometric Measurements

Bodyweight (kg) and height (cm) were measured. BMI was calculated as bodyweight (kg) divided by height in  $(m^2)$  (kg/m<sup>2</sup>).

#### Sample Collection and Biochemical Estimations

Five mL of fasting blood sample was collected for biochemical estimations, such as glucose, glycated hemoglobin (HbA1c), and insulin; FA analysis; and DNA isolation. Fasting plasma glucose was measured by the glucose oxidase method (LyphoCHEKTMAGAPPE). HbA1c was measured using ion exchange resin method on spectrophotometer (Nycocard READER, Abbott). Plasma insulin was measured using a commercially available human insulin kit (Accu- Bind, Monobind Inc., US).

## Calculation of HOMA-IR and HOMA-B

The HOMA of IR index (HOMA-IR) was calculated using the following formula 7:

HOMA-IR = Fasting glucose  $_{(mmol/dl)}$  × Fasting plasma insulin  $_{(\mu IU/ml)}/22.5$ .

HOMA-B was calculated using the following formula 7: HOMA-B=  $20 \times$  Fasting insulin ( $\mu$ IU/ml)/fasting glucose (mmol/ml) - 3.5.

## **DNA** Isolation and Quantification

The isolation of DNA from whole blood was performed using a standardized protocol by Sergeant et al., 2012<sup>8</sup>. The concentration of DNA per sample was determined using bio-spectrophotometer and stored at  $-20^{\circ}$ C until further analysis. The integrity of the genomic DNA was examined on 0.8% agarose gel. DNA in the gel was visualized using gel documentation system (Biorad). The DNA was quantified by measuring optical density at 260 nm and 280 nm in a bio-spectrophotometer. The ratio of 260/280nm was calculated for measuring the purity of DNA sample, and the DNA samples for which the ratio was 1.7–1.9 was stored at  $-20^{\circ}$ C until further analysis.

## **SNP** Selection

The SNP rs174575 of FADS2 was selected according to previous publications <sup>9-12</sup> and identified using the dbSNP database 13 based on the National Centre for Biotechnology Information (NCBI) <sup>12</sup>. The primer pair for SNP rs174575 (designed for the study) involved in the study was as follows: Forward: AGGCAGAT-GGACCTGGATTTGA and Reverse TGGCTTG-CAAATAGACTCATCTCC. PCR conditions included initial desaturation at 95°C for 3 min, followed by 95°C for 1 min, 58°C for 30 sec, 72°C for 1 min for 35 cycles,

final extension at 72°C for 10 min and holding at 4°C. The amplified products were purified using PCR-clean up kit (Sigma-Aldrich); the products were sequenced using Sanger sequencing method at Eurofins Genomics India Pvt. Ltd. Bengaluru, Karnataka, India.

#### **Statistical Analysis**

Statistical analyses were performed using SPSS (version 20.0, IBM, Armonk, NY, USA). The Kolmogorov–Smirnov test was used to assess the normality of variables. Normal quantitative variables were reported as mean  $\pm$  SD. To compare clinical characteristics, student's t-test and K-independent nonparametric analysis (Mann–Whitney U test) were used for the normal and non-normal distribution, respectively. Pearson's coefficient was used to associate some of the normal variables with each other in all subjects. One-way analysis of variance and Bonferroni correction tests were used to compare the variables between genotypes in each group.

#### Results

#### General Characteristics of the Study Population

Table 1 depicts the anthropometric parameters of the study population. Age and weight showed statistically significant difference between the two groups.

	Control (N = 216)	Diabetic (N = 213)	p-value
	(mean±SD)	(mean±SD)	
Age (yrs)	47.44± 10.16	51.03 ± 8.25	<0.001
Weight (Kg)	$60.15 \pm 12.06$	$62.94 \pm 10.32$	0.011
Height (Cm)	$158.98 \pm 13.98$	$160.6 \pm 14.18$	0.23
BMI (Kg/m <sup>2</sup> )	$23.961 \pm 4.749$	$24.395 \pm 4.018$	0.308

**Table 1:** Anthropometric Parameters of Study Population

\*P-value  $\leq 0.05$  was considered statistically significant.

\*Student t-test: data are shown as mean  $\pm$  SD.

# Comparison of Glycemic Profile between the two Groups.

The mean FBS (mg/dL), HbA1c (%), and insulin (pmol/L) levels in the control group were lower than those in the diabetic group. FBS, HbA1c, and insulin

showed a high and statistically significant difference between the two groups (p < 0.001).

Additionally, HOMA-IR and HOMA-B exhibited a statistically significant difference between the two groups (Table 2).

Table 2: Comparison of Glycemic Profile between the Control and Diabetic Gu	roups
---	-------

Parameters	Control	Diabetic	p-value
	(N = 216)	(N = 213)	
	(mean±SD)	(mean±SD)	
FBS	$97.41 \pm 14.04$	$192.77 \pm 68.19$	< 0.001*
(mg/dL)			
HbA1c	$4.63 \pm 0.82$	6.88 ± 1.92	< 0.001*
(%)			
Insulin	30.59± 8.45	41.17 ± 3.37	< 0.001*
(pmol/L)			
HOMA-IR*	1.007 (0.865-1.208)	2.57 (2.016-3.314)	< 0.001
HOMA-B*	45.633 (32.98-63.139)	19.037 (13.066-28.606)	< 0.001

\*P-value  $\leq 0.05$  was considered statistically significant.

\*Student t-test: data are shown as mean  $\pm$  SD.

\*Mann-Whitney U test: data are shown as median (interquartile range).

Allele and Genotype Frequencies for FADS 2 rs174575 CC genotype was wild type homozygote genotype for rs174575 C>G, while GG was homozygous recessive variant genotype. CG was heterozygous genotype for rs174575. The allele frequency of C and G was 0.96 (96%) and 0.04 (4%), respectively, in the control group; in the diabetic group, is the frequency was 0.91 (91%) and 0.09 (9%), respectively. For the control and diabetic groups, the genotype frequency of CC, CG, and GG was 0.84 (95%), 0.1472 (4%), and 0.0064 (1%) and 0.807 (84%), 0.1770 (14%), and 0.0144 (2%), respectively. SNP is in Hardy Weinberg Equilibrium (HWE)-P= 1.732 (P > 0.05).

Comparison of the Glycemic Profile Composition between the Diabetic subjects Based on Genotype To compare glycemic profile with the genotype, the following three models were used in this study: additive model (CC vs CG vs GG), dominant model (CC + CG vs GG), and recessive model (CC vs CG + GG). In the additive model (CC vs CG vs GG), a statistically significant difference was observed in FBS, HOMA-IR and HOMA- B between three genotypes with a p-value of 0.022, 0.043 and 0.018, respectively. In the dominant model (CC+CG vs GG), a statistically significant difference was observed in FBS, HOMA-IR and HOMA-B between three genotypes with a p-value of 0.010, 0.026 and 0.016 respectively. In the recessive model (CC vs CG+GG) statistically significant difference was observed in HOMA-B (p=0.027), HOMA-IR showed a p-value of 0.042 (Table 3).

Fable 3: Com	parison of Glycemi	c Profile between	the Diabetic Individuals	Using Different	Genotype Models
	2			6	21

	Additive Model (CC vs CG vs GG) (mean±SD)			Dominant Model (CC + CG vs GG) (mean±SD)		Recessive Model (CC vs CG + GG) (mean±SD)				
Parameters	CC (N=180)	CG (N=29)	GG (N=4)	p- value	CC + CG (N=209)	GG (N=4)	p- value	CC (N=180)	CG + GG (N=33)	p- value
FBS	$189.19\pm5.05$	$202.88\pm12.66$	$280.33\pm33.87$	0.022	$191.10\pm4.68$	$280.24 \pm 33.87$	0.010	189.19 ± 5.05	$213.15 \pm 11.97$	0.047
HbA1C	$6.83\pm0.14$	$7.13\pm0.36$	$7.65\pm0.96$	0.540	$6.87\pm0.13$	$7.65\pm0.96$	0.425	$6.83\pm0.14$	$7.24 \pm 0.34$	0.323
Insulin	$41.23\pm0.27$	$40.94\pm0.68$	$41.57\pm0.67$	0.879	$41.17\pm0.96$	$41.57\pm0.67$	0.741	$41.23\pm0.27$	$41.07\pm0.23$	0.637
HOMA-IR	$2.78\pm0.08$	2.97 ± 0.19	$4.04\pm0.51$	0.043	$2.80\pm0.07$	$4.04\pm0.51$	0.026	$2.78\pm0.08$	3.10 ± 0.18	0.042
HOMA-B	$20.90\pm0.63$	$17.92 \pm 1.58$	11.76 ± 4.23	0.018	$20.49\pm0.59$	$11.78\pm4.23$	0.016	$20.90\pm0.63$	17.17 ± 1.49	0.027

## Discussion

A large number of genetic variants have been investigated for the prediction value of T2DM<sup>13</sup>, and they marginally improved prediction beyond noninvasive characteristics in those studies because the accuracy of prediction relies on many factors, such as the number of genes involved, the frequency of risk alleles, and the risks correlated with genotypes 14. The SNP rs174575 of FADS2 gene was selected in the presented study because as per the literature the SNP rs174575 has a combination of two desirable factors (i) It had known linkage disequilibrium (LD) throughout the region, the promoter and intragenic region of FADS2. (ii) It had minor allele frequencies sufficiently prevalent to permit their use in tests of gene-environment and gene-gene interaction<sup>15</sup>. Of the three genotype models deduced to study the relationship between genotype and insulin resistance, the recessive model (CC vs CG+GG) was selected based on the number of subjects per group in each model. From the study results it is observed

that the HOMA-IR and HOMA-B showed statistically significant difference in the recessive model. The current study findings showed that HOMA-IR was higher in the minor allele carriers when compared to wild type allele and the difference was statistically significant whereas the HOMA-ß was lower in the minor allele carriers. Similar results were observed by Kim et al., 2011 in Korean normoglycemic men<sup>16</sup>. According to Steer et al., the desatuarse enzyme activity varies between the genotype, thereby altering PUFA metabolism<sup>15</sup>. This is of importance because PUFA serve as biological ligands to PPAR- $\gamma$  (Peroxisome proliferator-activated receptors-gamma) is closely associated with IR (Insulin resistance), Mets (Metabolic Syndrome), and DM (Diabetes mellitus)<sup>17-19</sup>. Based on this a suggestive mechanism for the role of rs174575 in T2DM can be derived from this study as depicted in figure 1 (a) and (b). Studies have shown that major homozygotes C have normal PUFA metabolism<sup>13</sup> because of normal desaturase and elongase activity and produced more omega 3

FAs and anti-inflammatory bioactive mediators, such as leukotrienes and prostaglandins, which act as biological ligands for PPAR- $\gamma$ . Nevertheless, biological ligands are preferred by PPAR- $\gamma$  when compared to chemical

ligands. Moreover, PUFA blocks NF-kappa B (Nuclear factor Kappa B) reducing inflammation. Together, all factors may increase insulin sensitivity, thereby decreasing insulin resistance Figure 1 (a).



**Figure 1 (a):** Suggestive mechanism of action: rs174575, CC homozygotes interaction with PPAR- $\gamma$  as derived from the study (created using Biorender.com)

Whereas in the minor G allele carriers of rs174575, a PUFA metabolism is altered due to altered desaturase gene expression<sup>13</sup>. Reduced PUFA levels, mainly omega 3 FAs, increased LA (from dietary major sources, such

as seed oils), and AA (Arachidonic acid) accumulation activates NF-Kappa B, transcribing COX (Cyclooxygenase) and lipo-oxygenase genes and increasing inflammation. This reduces insulin sensitivity and increases insulin resistance as shown in figure 1 (b).



Figure 1(b): Suggestive mechanism of action of - rs174575-G allele carriers and insulin resistance via interaction with PPAR- $\gamma$  as derived from the study

Therefore, this complex interplay between insulin resistance and gene variants needs to be better understood and elucidated at a molecular level.

## Conclusion

The distribution of rs174575 genotypes differed significantly between the subjects and controls in the present study, and we suggest that having a minor allele genotype alone may significantly increase the risk of incidence T2DM. The study revealed that genetic variation in FADS2 could be an additional facet to consider while studying the risk factors of T2DM.

## Author's Contribution

• Author 1: Conceived and planned the experiments. carried out the experiments. contributed to sample preparation, contributed to the interpretation of the results and took the lead in writing the manuscript.

• Author 2: Conceived of the presented idea and encouraged author 1 to investigate and supervised the findings of this work.

• Author 3, Author 4, - provided critical feedback and helped shape the research, analysis and manuscript.

## Conflict of interest

None.

# References

 Nowak C, Sundstrom J, Gustafsson S, Giedraitis V, Lind L, Ingelsson E, et al. Protein Biomarkers for Insulin Resistance and Type 2 Diabetes Risk in Two Large Community Cohorts. *Diabetes*. 2016; 65:276–284.
 Wang P, Fiaschi-Taesch NM, Vasavada RC, Scott DK, García-Ocana A, Stewart AF. Diabetes mellitus -advances and challenges in human beta-cell proliferation. *Nature Reviews Endocrinology*. 2015; 11:201–212.

3. Unnikrishnan R, Anjana R, MohanV. Diabetes in South Asians: Is the Phenotype Different? *Diabetes*. 2014; 63:53–55. 39

4. Schaeffer L, Gohlke H, Muller M, Heid IM, Palmer LJ, Kompauer I, et al. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. *Hum Mol Genet*. 2006;15(11):1745–1756. 159

5. Malerba G, Schaeffer L, Xumerle L, Klopp N, Trabetti E, Biscuola M, et al. SNPs of the FADS gene cluster are associated with polyunsaturated fatty acids in a cohort of patients with cardiovascular disease. *Lipids*. 2008;43(4):289–299. 160 6. Standards of Medical Care in Diabetes—2014. Diabetes Care 2014;37(Suppl. 1): S14–S80. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2014;37(Suppl. 1): S81–S90. *American Diabetes Association Diabetes Care*. 2014 Mar; 37(3): 887-887. 23

7. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia*. 1985;28(7):412-9.

8. Sergeant S, Hugenschmidt CE, Rudock ME, Ziegler JT, Ivester P, Ainsworth HC et al, Differences in arachidonic acid levels and fatty acid desaturase (FADS) gene variants in African Americans and European Americans with diabetes or the metabolic syndrome. *Br J Nutr.* 2012; 107(4): 547–555.

9. Kinsell LW, Walker G, Michaels GD, Olson FE. Dietary fats and the diabetic patient. *N Engl J Med.* 1959; 261:431–434. 200-204

10. Krauss-Etschmann S, Shadid R, Campoy C, Hoster E, Demmelmair H et al., Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: A European randomized multicenter trial. *Am J Clin Nutr.* 2007;85: 1392-1400.

11. Koletzko B, Demmelmair H, Schaeffer L, Illig, Heinrich J. Genetically determined variation in polyunsaturated Fatty Acid metabolism may result in different dietary requirements. *Nestle Nutr Workshop Ser Pediatr Program.* 2008; 62: 35- 49.

12. National Center for Biotechnology Information (NCBI) Internet. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 1988 – cited 2017 Apr 06. Available from: https://www.ncbi.nlm.nih.gov/.

13. Steer CD, Davey Smith G, Emmett PM, Hibbeln JR, Golding J. FADS2 polymorphisms modify the effect of breastfeeding on child IQ. *PLoS One.* 2010;5(7):11570. 256-257

14. Scaioli E, Liverani E, Belluzzi A. The Imbalance between n-6/n-3 Polyunsaturated Fatty Acids and Inflammatory Bowel Disease: A Comprehensive Review and Future Therapeutic Perspectives. *Int J Mol Sci.* 2017;18(12):2619.

15. He Z, Zhang R, Jiang F, Zhang H, Zhao A, Xu B, et al. FADS1-FADS2 genetic polymorphisms are associated with fatty acid metabolism through changes in DNA methylation and gene expression. *Clin Epigenetics*. 2018;10(1):113.

16. Kim OY, Lim HH, Yang LI, Chae JS, Lee JH. Fatty acid desaturase (FADS) gene polymorphism and insulin resistance in association with serum phospholipid polyunsaturated fatty acid composition in healthy Korean men: Cross-sectional study. *Nutr Metab.* 2011; 8:24.

17. Nakamura MT, Nara TY. Structure, function, and dietary regulation of delta6, delta5, and delta9 desaturases. *Annu Rev Nutr.* 2004; 24; 345-76.

18. Merino DM, Johnston H, Clarke S, Roke K, Nielsen K, Badawi A, et al. Polymorphisms in FADS1 and FADS2 alter desaturase activity in young Caucasian and Asian adults. *Mol Genet Metab.* 2011;103;171-8.

19. Moseti D, Regassa A, Kim WK. Molecular Regulation of Adipogenesis and Potential Anti-Adipogenic Bioactive Molecules. *Int J Mol Sci.* 2016 Jan 19;17(1):124. 260.